UCB Joins with ILAE and IBE to Encourage World Health Assembly Members to Continue Recognition of Epilepsy as Global Health Priority

- Representatives from the International League against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE), alongside prominent members of the Global epilepsy community, are meeting this week to encourage World Health Assembly (WHA) members and the World Health Organization (WHO) to continue to recognize epilepsy as a global health priority in countries around the world. Coinciding with the 71st World Health Assembly, advocates will focus on progressing the milestone 2015 WHO Resolution on epilepsy to encourage countries to prioritise epilepsy at national levels, including promoting awareness, eliminating stigma of the disease, expanding research capacity, improving monitoring and surveillance, and expanding access to care. One of the particular areas of focus will be how to better develop and shape public health policy to better support people living with epilepsy achieve a better quality of life. Epilepsy is the most common serious disease of the brain,[1] affecting 65 million people around the world.[2] In developing countries, 60% to 90% of people with epilepsy receive no treatment due to inadequacies in healthcare resources and delivery and due to social stigma.[1] "This World Health Assembly can be a turning point for the epilepsy community. Our organizations are fully committed to seeking international support to the 2015 Resolution on epilepsy"  said Martin Brodie and Samuel Wiebe, respectively IBE President and ILAE President, in a joint statement. "We hope that this renewed momentum will inspire the creation of a broad-ranging coalition carrying on further innovative programs and activities consistent with the objectives of the Resolution" they added.  Supporting these efforts, ILAE and IBE have convened a distinguished expert panel to highlight recent progress and global achievements made to improve awareness and management of epilepsy by WHA countries, and to identify some of the outstanding challenges which unfortunately still remain. These include significant gaps and disparities in epilepsy management, awareness and access to effective treatment around the world, which contribute to inequality and stigma. "As Global leaders in epilepsy, UCB is proud to support the ILAE and the IBE in their continued efforts to improve the lives of people with epilepsy throughout the world" explained Bruce Lavin, Head of Neurology External Engagement and Policy at UCB. "We share a joint commitment to provide additional value to people living with epilepsy around the world. Whether by improving epilepsy care by creating tools, engaging with stakeholders to raise awareness about the complex spectrum of epilepsy, or facilitating the exchange of information and developing standards and guidelines which support people at each stage of their epilepsy journey". In convening this meeting, the group hopes to inspire the creation of a broader public-private coalition and develop an action plan for further innovative programs and activities consistent with the objectives of the WHO Resolution. The ILAE and IBE have a long standing formal collaboration with the WHO, which was renewed by the WHO's Executive Board at the their 140th Annual session in 2017. This collaboration provides a continued platform to help ensure epilepsy is recognized as a health priority worldwide, and that the human and civil rights of people with epilepsy are enhanced and protected wherever they might live. About Epilepsy[2],[3] Epilepsy is a disease of the brain affecting approximately 65 million people worldwide.[2] It is defined as either the occurrence of two or more unprovoked seizures >24 hours apart or one unprovoked (or reflex) seizure and a probability of further seizures occurring over the next 10 years that is similar to the general recurrence risk (at least 60%) after two unprovoked seizures or diagnosis of an epilepsy syndrome.[3] Although epilepsy may be linked to factors such as health conditions, race and age, it can develop in anyone at any age, and approximately 1 in 26 people will develop epilepsy in their lifetime.[2] About UCB in Epilepsy   UCB has a longstanding commitment to improving the lives of people with epilepsy around the world. With over 20 years of experience in the research and development of antiepileptic drugs, our goal is to become a preferred partner for the global epilepsy community, improving knowledge about and access to effective solutions to help patients better manage their individual epilepsy journeys. We strive to partner and create super-networks with world-leading scientists and clinicians in academic institutions, pharmaceutical companies and other organizations who share our goals. At UCB, we are inspired by patients, and driven by science in our commitment to support people with epilepsy. About UCB  UCB, Brussels, Belgium (http://www.ucb.com ) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. With approximately 7500 people operating in 40 countries, the company generated revenue of €4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news Forward looking statements   This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations,  changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations. There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement. References: